Search
Technetium Tc-99m succimer
go.drugbank.com/drugs/DB09436Approvedfunction in patients with renal parenchymal disorders. … It works by binding to the cortical region of the kidneys. Technetium Tc-99m succimer is used with gamma scintigraphy or single-photon emission computed tomography (SPECT).
Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsTocofersolan
go.drugbank.com/drugs/DB11635ApprovedD-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis [L2371]. … In addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery [MSDS].
Synonyms: D-.ALPHA.-TOCOPHEROL POLYETHYLENE GLYCOL 1000 SUCCINATE, TPG-SMixtures: Eye Health Areds 2 FormulaBasiliximab
go.drugbank.com/drugs/DB00074ApprovedInvestigationalIt is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes … known as CD25 antigen) on the surface of activated T-lymphocytes.
Categories: Interleukin-2 Receptor Antagonist, Interleukin-2 Receptor Blocking AntibodyProducts: SIMULECT® LIOFILIZADO PARA INYECCION 20 MG/VIAL, SIMULECT 20 MG İNFÜZYON VEYA ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETGalactose
go.drugbank.com/drugs/DB11735ApprovedInvestigationalWithdrawnThere are even proposals for its use in accelerating senescence in mice, rats, and Drosophila, for its association with ovarian cancer, or even for the potential treatment of focal segmental glomerulosclerosis … Nevertheless, none of these ongoing studies have yet provided formal elucidation for their proposals. As a naturally occurring sugar, it may be found in a number dairy products.
Mixtures: Levovist - Pws IV (4g Granules /vial)Categories: microparticles of galactoseLErafAON
go.drugbank.com/drugs/DB04973InvestigationalPhase I/II trials commenced in March 2001 and were ongoing as of June 2003. … NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation
Estradiol cypionate
go.drugbank.com/drugs/DB13954ApprovedVet approvedin potency and in estrogenic effects. … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction
Mixtures: OBAT SUNTIK KB II, FEMELIN®Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCalaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalAsparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. … This forms the basis of asparaginase treatment in ALL [A40270], [A40273], [F2432].
Categories: Compounds used in a research, industrial, or household setting, L-asparaginase containing drugsCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigational[L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigational[L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for
RTA 744
go.drugbank.com/drugs/DB05920InvestigationalAnthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current therapies do not cross the blood-brain barrier … RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.